— Know what they know.
Not Investment Advice

BGNE NASDAQ

BeiGene, Ltd.
1W: +1.3% 1M: -10.6% 3M: -21.2% 1Y: +4.0% 3Y: -29.5% 5Y: +10.6%
$184.71
Last traded 2025-01-02 — delisted
NASDAQ · Healthcare · Biotechnology · $20.2B mcap · 7M float · 5.11% daily turnover

Cash Flow Trends

Operating Cash Flow
$1.1B +901.8% ▲
Capital Expenditures
$186M +64.9% ▲
5Y CAGR: -4.1%
Free Cash Flow
$942M +240.6% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$2.0B +460.2% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$1.4B-$2.0B-$882M-$645M$287M
Depreciation & Amort.$46M$66M$88M$172M$142M
Stock-Based Comp.$241M$303M$368M$442M$511M
Change in Working Capital-$118M$132M-$371M-$157M$0
Other Non-Cash Items-$13M$3M-$361M$22M$179M
Operating Cash Flow-$1.3B-$1.5B-$1.2B-$141M$1.1B
— Investing Activities —
Capital Expenditures-$315M-$469M-$562M-$493M-$186M
Acquisitions (Net)$52M-$1.4B$0$0$0
Investment Purchases-$2.2B-$17M-$17M-$19M-$12M
Investment Sales$3.1B$1.6B$673M$3M$3M
Other Investing-$52M$1.4B-$15M-$39M-$82M
Investing Cash Flow$641M$1.1B$60M-$548M-$276M
— Financing Activities —
Net Debt Issuance$102M-$66M$361M$145M$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$93M$47M$56M$48M$1.1B
Financing Cash Flow$3.6B-$19M$416M$193M$1.1B
Net Change in Cash$3.0B-$508M-$689M-$547M$2.0B
Cash End of Period$4.4B$3.9B$3.2B$2.6B$4.6B
Free Cash Flow-$1.6B-$2.0B-$1.8B-$670M$942M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms